Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Psoriasis | 17 | 2020 | 1739 | 3.22 | Why? |
| Botulinum Toxins, Type A | 4 | 2019 | 134 | 2.04 | Why? |
| Dermatologic Agents | 6 | 2020 | 489 | 1.80 | Why? |
| Biological Products | 7 | 2020 | 2331 | 1.56 | Why? |
| Neuromuscular Agents | 3 | 2019 | 87 | 1.55 | Why? |
| Muscle Spasticity | 3 | 2019 | 117 | 1.50 | Why? |
| Dermatitis, Exfoliative | 2 | 2019 | 50 | 1.37 | Why? |
| Sunlight | 2 | 2021 | 287 | 1.20 | Why? |
| Skin Diseases | 8 | 2021 | 2509 | 1.03 | Why? |
| Dermatology | 8 | 2020 | 1999 | 0.98 | Why? |
| Dermatitis, Atopic | 3 | 2019 | 714 | 0.84 | Why? |
| Kaposi Varicelliform Eruption | 1 | 2019 | 5 | 0.80 | Why? |
| Extracorporeal Shockwave Therapy | 1 | 2019 | 12 | 0.78 | Why? |
| Ultraviolet Rays | 2 | 2021 | 1272 | 0.78 | Why? |
| Pemphigus, Benign Familial | 1 | 2018 | 14 | 0.77 | Why? |
| Acetylcholine Release Inhibitors | 1 | 2019 | 32 | 0.76 | Why? |
| Muscle Contraction | 1 | 2019 | 60 | 0.75 | Why? |
| Salivation | 1 | 2018 | 7 | 0.74 | Why? |
| Acne Vulgaris | 2 | 2020 | 198 | 0.74 | Why? |
| Goldenhar Syndrome | 1 | 2018 | 3 | 0.74 | Why? |
| Skin | 4 | 2018 | 2096 | 0.73 | Why? |
| Submandibular Gland | 1 | 2018 | 29 | 0.73 | Why? |
| Sialorrhea | 1 | 2018 | 24 | 0.72 | Why? |
| Interleukin-17 | 2 | 2020 | 602 | 0.71 | Why? |
| Parotid Gland | 1 | 2018 | 53 | 0.71 | Why? |
| Cumulative Trauma Disorders | 1 | 2017 | 27 | 0.69 | Why? |
| Hazardous Waste | 1 | 2017 | 14 | 0.69 | Why? |
| DNA Repair Enzymes | 1 | 2017 | 33 | 0.67 | Why? |
| Arthritis, Psoriatic | 3 | 2018 | 625 | 0.67 | Why? |
| Mycosis Fungoides | 1 | 2017 | 48 | 0.65 | Why? |
| Sunscreening Agents | 1 | 2017 | 63 | 0.64 | Why? |
| Common Variable Immunodeficiency | 1 | 2019 | 195 | 0.62 | Why? |
| Radiation Protection | 1 | 2017 | 78 | 0.61 | Why? |
| Thyroiditis | 1 | 2017 | 104 | 0.60 | Why? |
| Vitamin D | 3 | 2021 | 2904 | 0.60 | Why? |
| Hand Dermatoses | 2 | 2018 | 284 | 0.59 | Why? |
| Water | 2 | 2018 | 765 | 0.57 | Why? |
| Methotrexate | 1 | 2019 | 471 | 0.56 | Why? |
| Eczema | 1 | 2017 | 227 | 0.51 | Why? |
| Myalgia | 1 | 2019 | 1015 | 0.49 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.47 | Why? |
| Muscle, Skeletal | 1 | 2019 | 915 | 0.46 | Why? |
| Ambulatory Care Facilities | 2 | 2020 | 2063 | 0.44 | Why? |
| Behavior, Addictive | 1 | 2017 | 535 | 0.40 | Why? |
| Skin Neoplasms | 2 | 2017 | 1679 | 0.31 | Why? |
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 9335 | 0.31 | Why? |
| Antirheumatic Agents | 2 | 2018 | 3023 | 0.31 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.31 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.31 | Why? |
| Ustekinumab | 2 | 2018 | 216 | 0.30 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.30 | Why? |
| Vitamin D Deficiency | 2 | 2018 | 1782 | 0.30 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.30 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.23 | Why? |
| Receptors, Interleukin-17 | 1 | 2020 | 9 | 0.22 | Why? |
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2021 | 108 | 0.21 | Why? |
| Italy | 9 | 2021 | 38444 | 0.21 | Why? |
| Humans | 50 | 2021 | 930598 | 0.21 | Why? |
| Treatment Outcome | 12 | 2019 | 51732 | 0.21 | Why? |
| Physical Therapy Modalities | 2 | 2019 | 1090 | 0.20 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2021 | 159 | 0.20 | Why? |
| Dihydroxycholecalciferols | 1 | 2018 | 3 | 0.20 | Why? |
| Tinea Versicolor | 1 | 2018 | 6 | 0.20 | Why? |
| Etanercept | 1 | 2020 | 162 | 0.20 | Why? |
| Ultraviolet Therapy | 1 | 2021 | 138 | 0.19 | Why? |
| Knee | 1 | 2018 | 35 | 0.19 | Why? |
| Ointments | 1 | 2018 | 54 | 0.19 | Why? |
| Nasopharyngitis | 1 | 2018 | 16 | 0.19 | Why? |
| Female | 29 | 2021 | 380317 | 0.19 | Why? |
| Age of Onset | 2 | 2018 | 557 | 0.18 | Why? |
| Toll-Like Receptors | 1 | 2021 | 365 | 0.18 | Why? |
| Pyoderma Gangrenosum | 1 | 2018 | 41 | 0.18 | Why? |
| Administration, Cutaneous | 1 | 2018 | 229 | 0.18 | Why? |
| Hand Joints | 1 | 2017 | 31 | 0.17 | Why? |
| Interleukin-23 | 1 | 2018 | 64 | 0.17 | Why? |
| Nevus, Epithelioid and Spindle Cell | 1 | 2017 | 17 | 0.17 | Why? |
| Remission Induction | 2 | 2018 | 950 | 0.17 | Why? |
| Garbage | 1 | 2017 | 15 | 0.17 | Why? |
| Tattooing | 1 | 2017 | 27 | 0.17 | Why? |
| Coffee | 1 | 2018 | 79 | 0.17 | Why? |
| Half-Life | 1 | 2018 | 298 | 0.17 | Why? |
| Medication Adherence | 2 | 2020 | 1270 | 0.17 | Why? |
| Adult | 21 | 2021 | 244371 | 0.16 | Why? |
| Male | 25 | 2021 | 367725 | 0.16 | Why? |
| Injections | 1 | 2018 | 237 | 0.16 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.16 | Why? |
| Adalimumab | 1 | 2020 | 389 | 0.16 | Why? |
| Immunosuppressive Agents | 3 | 2020 | 6331 | 0.16 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.16 | Why? |
| Nutritionists | 1 | 2017 | 82 | 0.16 | Why? |
| Arm | 1 | 2017 | 159 | 0.16 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.15 | Why? |
| Suction | 1 | 2018 | 297 | 0.15 | Why? |
| Drug Substitution | 1 | 2019 | 385 | 0.15 | Why? |
| Injections, Intramuscular | 1 | 2018 | 800 | 0.15 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.15 | Why? |
| Stroke | 1 | 2019 | 8839 | 0.15 | Why? |
| Pruritus | 1 | 2017 | 215 | 0.14 | Why? |
| Weight Gain | 1 | 2020 | 552 | 0.14 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.14 | Why? |
| Hidradenitis Suppurativa | 1 | 2020 | 309 | 0.14 | Why? |
| Medical History Taking | 1 | 2017 | 350 | 0.14 | Why? |
| Dermatomyositis | 1 | 2017 | 193 | 0.14 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.14 | Why? |
| Mice, Knockout | 1 | 2020 | 1815 | 0.14 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.14 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.14 | Why? |
| Dermatitis, Allergic Contact | 1 | 2017 | 185 | 0.13 | Why? |
| Body Weight | 1 | 2020 | 1074 | 0.13 | Why? |
| Overweight | 1 | 2020 | 916 | 0.13 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2019 | 398 | 0.13 | Why? |
| Lymphocyte Subsets | 1 | 2020 | 987 | 0.13 | Why? |
| Dermoscopy | 1 | 2017 | 346 | 0.12 | Why? |
| Withholding Treatment | 1 | 2019 | 798 | 0.12 | Why? |
| Orthomyxoviridae Infections | 1 | 2020 | 1001 | 0.12 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.12 | Why? |
| Dermatologists | 1 | 2017 | 435 | 0.11 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.11 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.11 | Why? |
| Urticaria | 1 | 2018 | 472 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.11 | Why? |
| Metabolic Syndrome | 1 | 2018 | 810 | 0.10 | Why? |
| Middle Aged | 14 | 2020 | 270681 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.09 | Why? |
| Severity of Illness Index | 6 | 2020 | 48226 | 0.09 | Why? |
| Diagnosis, Differential | 3 | 2020 | 7220 | 0.09 | Why? |
| Obesity | 2 | 2020 | 7388 | 0.09 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.09 | Why? |
| Chronic Disease | 2 | 2020 | 5139 | 0.09 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.09 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.09 | Why? |
| Cystic Fibrosis | 1 | 2018 | 1104 | 0.09 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.09 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.08 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.08 | Why? |
| Patient Satisfaction | 1 | 2020 | 2517 | 0.08 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.08 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.08 | Why? |
| Time Factors | 3 | 2019 | 31397 | 0.08 | Why? |
| Immunoglobulins, Intravenous | 1 | 2019 | 2705 | 0.08 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.08 | Why? |
| Melanoma | 1 | 2017 | 1229 | 0.08 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.07 | Why? |
| Aged | 9 | 2020 | 215776 | 0.07 | Why? |
| Adolescent | 8 | 2020 | 86841 | 0.07 | Why? |
| Cell Phone | 1 | 2012 | 750 | 0.07 | Why? |
| Fear | 1 | 2020 | 3607 | 0.07 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.06 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.06 | Why? |
| Age Factors | 3 | 2019 | 21039 | 0.06 | Why? |
| Patient Education as Topic | 1 | 2012 | 1476 | 0.06 | Why? |
| Pediatrics | 1 | 2018 | 2969 | 0.06 | Why? |
| Telemedicine | 3 | 2020 | 25032 | 0.06 | Why? |
| Animals | 3 | 2021 | 78931 | 0.06 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.06 | Why? |
| Occupational Diseases | 1 | 2017 | 2787 | 0.06 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.05 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.05 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.05 | Why? |
| Mice | 1 | 2020 | 21357 | 0.05 | Why? |
| Young Adult | 5 | 2017 | 93724 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Exercise | 1 | 2020 | 6771 | 0.05 | Why? |
| Back | 1 | 2018 | 10 | 0.05 | Why? |
| Ketoconazole | 1 | 2018 | 14 | 0.05 | Why? |
| Torso | 1 | 2018 | 24 | 0.05 | Why? |
| Drug Tolerance | 1 | 2019 | 100 | 0.05 | Why? |
| Students | 1 | 2017 | 5255 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.04 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.04 | Why? |
| Skin Physiological Phenomena | 1 | 2017 | 27 | 0.04 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.04 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.04 | Why? |
| Extremities | 1 | 2018 | 179 | 0.04 | Why? |
| Skin Aging | 1 | 2018 | 55 | 0.04 | Why? |
| Melanocytes | 1 | 2017 | 44 | 0.04 | Why? |
| Administration, Topical | 1 | 2018 | 272 | 0.04 | Why? |
| Depression | 1 | 2021 | 14116 | 0.04 | Why? |
| Physician-Patient Relations | 2 | 2020 | 1266 | 0.04 | Why? |
| Nutritional Physiological Phenomena | 1 | 2017 | 100 | 0.04 | Why? |
| Granuloma | 1 | 2017 | 88 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Child | 3 | 2018 | 70012 | 0.03 | Why? |
| Organ Specificity | 1 | 2018 | 1070 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Lower Extremity | 1 | 2019 | 593 | 0.03 | Why? |
| Cigarette Smoking | 1 | 2018 | 337 | 0.03 | Why? |
| School Health Services | 1 | 2017 | 294 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Europe | 2 | 2019 | 12702 | 0.03 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.03 | Why? |
| Precision Medicine | 1 | 2020 | 1477 | 0.03 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.02 | Why? |
| Australia | 1 | 2020 | 6306 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.02 | Why? |
| Internationality | 1 | 2019 | 3297 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Motivation | 1 | 2012 | 1640 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Pilot Projects | 1 | 2012 | 5182 | 0.01 | Why? |
| Attitude to Health | 1 | 2012 | 2002 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.01 | Why? |